papaverine/hemorrhage

OBJECTIVE To evaluate the techniques and efficacy of intracranial intraarterial papaverine infusion for symptomatic vasospasm after subarachnoid hemorrhage caused by aneurysm rupture. METHODS Papaverine was infused on 19 occasions in 14 patients, 6 hours to 2 days after spasm became apparent

This study examined the relationship between papaverine-sensitive and -insensitive components of vasospasm, arterial contractility and compliance, and time after subarachnoid hemorrhage (SAH) in dogs. Eighteen dogs underwent angiography and then two intracisternal injections of blood. Angiography

Intra-arterial infusion of papaverine was used clinically as a vasodilator for spastic arteries after subarachnoid hemorrhage, since in vitro experiment demonstrated that papaverine is one of the most potent vasodilators of human cerebral arteries following subarachnoid hemorrhage. The present

Complications associated with intraarterial papaverine infusion occurred in two patients treated for vasospasm due to subarachnoid hemorrhage (SAH). A 42-year-old male with an anterior communicating artery aneurysm underwent craniotomy and aneurysm clipping. Five days after the SAH occurred,

This report describes the successful treatment of cerebral vasospasm after subarachnoid hemorrhage with superselective intra-arterial infusion of papaverine hydrochloride. Thirty-seven vascular territories in 10 patients with symptomatic vasospasm were treated according to the following protocol.

Reports of intraarterial papaverine infusion as treatment for cerebral vasospasm are few and documented complications are uncommon. The authors report the case of a patient with paradoxical aggravation of cerebral arterial narrowing during selective intraarterial papaverine infusion intended to

OBJECTIVE Papaverine is used to vasodilate cerebral arteries undergoing vasospasm from subarachnoid hemorrhage. However, papaverine inhibits cellular respiration in vitro and could cause neurotoxicity in humans. METHODS We studied 5 consecutive patients with cerebral vasospasm who were treated with

BACKGROUND Selective intraarterial infusion of papaverine is used in the treatment of symptomatic cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage (SAH). Delays in instituting therapy for vasospasm can lead to irreversible cerebral infarction and a devastating outcome. Endovascular

The clinical efficacy of percutaneous transluminal angioplasty and intra-arterial papaverine infusion for treatment of vasospasm following subarachnoid hemorrhage was investigated. Between 1990 and 1993, 84 patients were treated for cerebral vasospasm in National Defense Medical College Hospital.

BACKGROUND Despite different treatments, cerebral vasospasm is still the most important cause of death in patients after subarachnoid hemorrhage. This study was conducted to explore the effect of intracisternal washing with papaverine on cerebral blood flow. METHODS This study was performed on 40

BACKGROUND Intra-arterial papaverine (IAP) has been described as a treatment for cerebral vasospasm refractory to standard therapy. METHODS We report a series of 15 consecutive patients with aneurysmal subarachnoid hemorrhage in which IAP was employed for the treatment of symptomatic vasospasm. All

Between July 1992 and January 1993 a prospective pilot study of the efficacy of intra-arterial papaverine in the management of clinically significant angiographically confirmed cerebral vasospasm arising as a consequence of aneurysmal subarachnoid haemorrhage was conducted. During this period 40

The management of vasospasm associated with traumatic subarachnoid haemorrhage presents many challenges. We present a 20-year-old male admitted after sustaining a closed head injury complicated by a Fisher grade III traumatic subarachnoid haemorrhage. Despite treatment with intravenous nimodipine he

Cerebral vasospasm is an important cause of delayed stroke after subarachnoid hemorrhage. Single-photon emission computed tomography (SPECT) of regional cerebral blood flow with (99m)Tc-hexamethyl propylenenamine oxime (HMPAO) was performed before and after intra-arterial papaverine treatment in 10

OBJECTIVE The goal in this study was to determine if there was a change in intracranial venous diameters after endovascular treatment of carotid distribution vasospasm caused by subarachnoid hemorrhage. METHODS The venous diameters were measured in all patients who received intraarterial papaverine